Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies

FDG-PET ([18F]fluorodeoxyglucose positron emission tomography) is frequently used to improve the differential diagnosis of dementia. However, a fundamental methodological issue of the reference area for the intensity normalization procedure is still unsolved. Here, we systematically compared the two most commonly used normalization methods to the cerebral and to the cerebellar metabolic rate for glucose with regard to detection and differentiation of dementia syndromes. FDG-PET imaging was performed on 19 subjects with early Alzheimer's disease, 13 subjects with early frontotemporal lobar degeneration and 10 subjects complaining of memory impairment, which had not been confirmed by comprehensive clinical testing. Images were normalized to either the cerebral or the cerebellar metabolic rate for glucose. Differences in relative regional glucose metabolism were assessed by voxelwise comparison. Analysis using the two normalization procedures revealed remarkable differential effects. Whereas cerebellar normalization was superior in identifying dementia patients in comparison to control subjects, cerebral normalization showed better results for differential diagnosis between types of dementia. These effects were shown for both, Alzheimer's disease and frontotemporal lobar degeneration. Relative hypermetabolism in comparison to the control group was only detected in both kinds of dementia using global normalization. The results indicate that normalization has a decisive impact on diagnostic accuracy in dementia. While cerebellar normalization seems to be more sensitive for early diagnosis, cerebral global normalization might be superior for differential diagnostic purposes in dementia syndromes.

[1]  美晴 佐村木,et al.  Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease , 2007 .

[2]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[3]  J. Morris The Clinical Dementia Rating (CDR) , 1993, Neurology.

[4]  Joel S. Karp,et al.  Concurrent CBF and CMRGlc changes during human brain activation by combined fMRI–PET scanning , 2005, NeuroImage.

[5]  L A Hansen,et al.  Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD , 2002, Neurology.

[6]  M. Freedman,et al.  Frontotemporal lobar degeneration , 1998, Neurology.

[7]  Alberto Pupi,et al.  Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Matthias L. Schroeter,et al.  Neural correlates of Alzheimer's disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients , 2009, NeuroImage.

[9]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[10]  Alexander Hammers,et al.  Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18 , 2008, Psychiatry Research: Neuroimaging.

[11]  Alexander Hammers,et al.  SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging , 2009, NeuroImage.

[12]  Albert Gjedde,et al.  Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson’s disease , 2009, NeuroImage.

[13]  C. DeCarli,et al.  What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.

[14]  D. Yves von Cramon,et al.  Neural networks in frontotemporal dementia—A meta-analysis , 2008, Neurobiology of Aging.

[15]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[16]  K. Ishii,et al.  Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  K. Zilles,et al.  Areas 3a, 3b, and 1 of Human Primary Somatosensory Cortex 2. Spatial Normalization to Standard Anatomical Space , 2000, NeuroImage.

[18]  C. Svarer,et al.  Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Tetsuya Mori,et al.  Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease , 2002, Journal of the Neurological Sciences.

[20]  Jerry L Prince,et al.  Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: MRI-Based Correction for Partial Volume Effects , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.

[22]  N. Foster,et al.  Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.

[23]  Gereon R. Fink,et al.  HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern , 1994, European Journal of Nuclear Medicine.

[24]  K. Ishii,et al.  Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  L. Mosconi,et al.  Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Ralph Buchert,et al.  Adjusted Scaling of FDG Positron Emission Tomography Images for Statistical Evaluation in Patients With Suspected Alzheimer's Disease , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[27]  Henry Brodaty,et al.  The differentiation of mild frontotemporal dementia from Alzheimer's disease and healthy aging by neuropsychological tests , 2004, International Psychogeriatrics.

[28]  Christian Degueldre,et al.  Voxel‐based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease , 2000, Human brain mapping.

[29]  D. Yves von Cramon,et al.  Towards a nosology for frontotemporal lobar degenerations—A meta-analysis involving 267 subjects , 2007, NeuroImage.

[30]  L. White,et al.  Structure of the human sensorimotor system. I: Morphology and cytoarchitecture of the central sulcus. , 1997, Cerebral cortex.

[31]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  I. Lemahieu,et al.  Differential Regional Cerebral Uptake of 18F-Fluoro-2-Deoxy-D-Glucose in Alzheimer’s Disease and Frontotemporal Dementia at Initial Diagnosis , 2001, European Neurology.

[33]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[34]  F Fazekas,et al.  Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  Klemens Scheidhauer,et al.  Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  J. S. Lee,et al.  18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.